Appili Therapeutics submitted funding proposals for infectious disease treatments, receiving $33.2 million to date.

From GlobeNewswire: 2025-03-18 07:22:22

Four new funding proposals, totaling US$117.5 million, have been submitted for review. Appili Therapeutics Inc. has submitted applications for federal funding opportunities to support urgent infectious disease treatments. The company, along with partners, applied for two solicitations from NIAID and two proposals to the US Medical CBRN Defense Consortium. Appili has received US$33.2 million in non-dilutive funding awards to date, showcasing its ability to compete for government funding. The Company has also received an update to its arrangement with the United States Air Force Academy for a biodefense vaccine candidate, ATI-1701.

In an update on the going-private transaction, Appili has extended the outside date to March 31, 2025, with Aditxt Inc. The transaction remains subject to Aditxt securing sufficient financing, and Appili expects it to close in the first quarter of 2025. For further details on the transaction, refer to Appili’s press release dated April 2, 2024. Appili Therapeutics is a biopharmaceutical company focused on developing therapies for infectious diseases, with a proven track record of securing government funding.



Read more at GlobeNewswire: Appili Therapeutics Announces Submission of U.S. Federal